The two major types of COXs are COX-1 and COX-2. The COX subtype involved in the basal state of the internal anal sphincter (IAS) smooth muscle tone is not known. To identify the COX subtype, we examined the effect of COX-1- and COX-2-selective inhibitors, SC-560 and rofecoxib,...
The two major types of COXs are COX-1 and COX-2. The COX subtype involved in the basal state of the internal anal sphincter (IAS) smooth muscle tone is not known. To identify the COX subtype, we examined the effect of COX-1- and COX-2-selective inhibitors, SC-560 and rofecoxib,...
Synthesis and biological evaluation of new phenidone ana- logues as potential dual cyclooxygenase (COX-1 and COX-2) and human lipoxy- genase (5-LOX) inhibitors. Farmaco 2005, 60, 7-13.Cusan, C.; Spalluto, G.; Prato, M.; Adams, M.; Bodensieck, A.; Bauer, R.; Tubaro, A.; ...
而不具有副作用,如果我们使用非选择性的NSAIDs将COX-1抑制了,则会导致患者出现各种副作用;COX-2在正常情况下仅表达于机体内的小部分部位,但是在机体受到损伤性因素的情况下,机体发生炎症反应的时候,COX-2会在全身各处增加表达,从而在全身各处起到致炎、致热、致痛的效果。
一、选择性COX-2抑制剂分类 选择性COX-2抑制剂对COX-2抑制作用强弱常以半抑制浓度(IC50)表示,即COX-2被抑制50%时抑制剂的浓度,若IC50(COX-2)小,则需较低浓度的抑制剂就可以达到抑制50%的COX-2的效果,即对COX-2的抑制作用强。一种药物其IC50(COX-1)/IC50(COX-2)比值越大,说明IC50(COX-2)越小,对CO...
A mechanistic perspective on the specificity and extent of COX-2 inhibition in pregnancy. Cyclo-oxygenase (COX)-2-specific inhibitors form one of the most commonly prescribed groups of pain relief drugs. Despite the known reproductive toxicity o... SW Vivian,Chan - 《Drug Safety》 被引量: 9...
Explanation of Cox-2 Inhibitors (Cox-2 inhibitor drugs) used to treat the pain of arthritis conditionsSearch Main menu Skip to primary content Skip to secondary content Home Candi chik1 Brusatol IKK-16 PD-1/PD-L1 Inhibitor 3 Pexidartinib VS-6063Powerful adjustments to your systemic resistant ...
【关键词】非甾体类抗炎药；环氧合酶；选择性环氧合酶-2抑制剂；心血管风险【中图分类号】R969 文献标志码A DOI ：10.3969/j.issn.2096-3351.2024.01.017 Research progress on cardiovascular risks induced by selective COX-2inhibitors HUANG Yong ，LI Di ，WANG Na ，RAN Yajuan ，LEI Xiaomei ...
June 6, 2012 COX-2 Inhibitors and Heart Risks Tracy Hampton, PhD JAMA. 2012;307(21):2247. doi:10.1001/jama.2012.5731 Full Text For years, nonsteroidal anti-inflammatory drugs that target the cyclooxygenase 2 (COX-2) enzyme have been linked to increased cardiovascular risks. New research ...
The currently licensed C5 inhibitors, given intravenously (IV) routinely, have also presented a difficulty in terms of quality of life (QoL). This has led to investigations into and the creation of new agents, some specifically designed to target various stages of the complement cascade, while ...